preterm birth. In this study, we compared between transabdominal and transvaginal CL measurement in order to establish practical recommendations for CL screening following routine mid-trimester anatomy scan. STUDY DESIGN: CL measurements were performed at 20-24 weeks' gestation, from January 2017 until April 2018, immediately after fetal anatomy scan. CL measurements were obtained transabdominally before (full bladder), and transvaginally after (empty bladder) voiding. The differences in CL and duration of transabdominal and transvaginal measurements were compared between the groups and adjustment was made for maternal age (MA), and body mass index (BMI). RESULTS: 468 women carrying a singleton pregnancy gave their informed consent to participate in the study. The overall duration for the fetal anatomy scan was 27AE5.3minutes. The duration of CL measured transabdominally was significantly shorter than the duration of CL measured transvaginally (6.9AE1.38min vs. 0.46AE0.3min, P<0.001). Difficulty in demonstrating the cervix transabdominally has been noted in 39 women (8.3%). The CL measured transvaginally was significantly longer than the CL measured transabdominally (42AE7.5mm vs 37.34AE6.8mm, p<0.001). The differences between the groups were unrelated to maternal age or BMI. All women whom transabdominal measurements of CL were above 35mm (66% of patients) had transvaginal CL above 25mm (98.2% of patient) (Fig 1) . CONCLUSION: Transvaginal measurement of CL is associated with discomfort and embarrassment. Additionally, the transvaginal measurement is a time-consuming procedure with a significant prolongation of fetal anatomy scan compared with the transabdominal approach. Therefore, transabdominal measurement of CL should be offered as an initial tool for cervical length screening. Transvaginal measurements of CL should be reserved for high-risk women (who had preterm delivery in the past), when there are difficulties in demonstrating the cervix abdominally, and for women with transabdominal measurements of less than 35mm.
1035 Five years' experience with universal preterm birth screening using transvaginal ultrasound for cervical length measurement We performed a retrospective analysis of patients with nonanomalous singleton gestations diagnosed with short CL in our tertiary medical center between Oct 2012 and Dec 2017 identified through our universal screening program. Screen positive was defined as CL <25mm in women at high risk (HR) for PTB, based on their obstetrical history, and <20mm for those considered low risk (LR). Program acceptance, screen positive rates, and gestational outcome were evaluated. The HR group was compared to LR for maternal, gestational and neonatal outcome data. RESULTS: During the study period 25,939 of 27,952 (92.8%) women who had 2 nd trimester anatomy scans elected CL screening. 430 (1.66%) patients were deemed screen positive: 135 (0.52%) in the HR group (CL <25mm) and 295 (1.14%) LR (CL <20mm). LR women were younger (29 vs 30.5 yrs., p¼0.018) and had lower gravidity (3 vs 5.4, p<0.001) and parity (0.56 vs 1.75, P<0.001) than HR. There was no difference in gestational age at diagnosis, ethnicity, or BMI. 181 (42%) delivered <37 weeks. 19/135 HR women (14%) were receiving 17-Hydroxyprogesterone. HR women used vaginal progesterone and cerclage equally (28%) and LR women used vaginal progesterone (55%) more frequently than cerclage (18%).Groups were similar for gestational age at birth (34w1d HR vs 34w0d LR, p¼0.78), neonatal death (6.67% HR vs 10.2% LR, p¼0.22) and admission to NICU (29% HR vs 27% LR, p¼0.76) but HR neonates had higher rates of necrotizing enterocolitis (6% vs 0.3%, p<0.001). The mean CL was shorter in the women who received cerclages (1.19 vs 1.66, P<0.001) and they were more likely to be high risk gravidas (P<0.001). There was no difference in neonatal outcomes between women using vaginal progesterone vs cerclage. CONCLUSION: Universal screening for PTB using transvaginal ultrasound for CL at time of 2 nd trimester anatomy scan is highly acceptable to patients. Over two thirds of screen positive patients were considered low risk for PTB and would not have otherwise been identified and eligible for PTB preventative interventions.
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